The Food and Drug Administration has approved Zepbound, a GLP-1 weight-loss drug from Eli Lilly & Co., for the treatment of moderate to severe sleep apnea certain patients with obesity. Photo courtesy ...

Over half of newborns with severe spina bifida experience sleep-disordered breathing, an often overlooked early threat to ...

Assessing mean apnea-hypopnea duration (MAD) in patients with OSA yields hypoxemia and symptom burden data not provided by the AHI or ODI.

Breakthrough sleep apnea medication AD109 shows promising results in phase 3 trials, potentially helping 30 million Americans with the condition.

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved to ...

Sleep apnea is a debilitating disease that many sufferers don’t even realize they have. Those afflicted with the condition ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a dual ...

DONGGUAN, GUANGDONG, CHINA, January 15, 2026 /EINPresswire.com/ -- As sleep disorders such as obstructive sleep apnea ...

Please provide your email address to receive an email when new articles are posted on . Individuals with moderate to severe obstructive sleep apnea had increased odds of having neovascular AMD.

Zepbound (tirzepatide) is a brand-name injection prescribed for treating sleep apnea. This article covers topics such as side effects, dosage, and how Zepbound works. Zepbound is available in ...

KBIA’s Rebecca Smith recently sat down with Dr. Mohammad Badran at the University of Missouri who studies sleep apnea to ...